25,553 DexCom, Inc. $DXCM Shares Acquired by Factory Mutual Insurance Co.

Factory Mutual Insurance Co. increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.8% during the third quarter, Holdings Channel reports. The institutional investor owned 563,383 shares of the medical device company’s stock after buying an additional 25,553 shares during the quarter. Factory Mutual Insurance Co.’s holdings in DexCom were worth $48,614,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Ascentis Independent Advisors purchased a new position in DexCom in the first quarter worth approximately $25,000. Latitude Advisors LLC purchased a new stake in shares of DexCom in the 3rd quarter valued at approximately $32,000. Hilton Head Capital Partners LLC increased its position in shares of DexCom by 242.3% in the 3rd quarter. Hilton Head Capital Partners LLC now owns 380 shares of the medical device company’s stock valued at $33,000 after purchasing an additional 269 shares during the last quarter. Wellington Grp LLC increased its position in shares of DexCom by 778.7% in the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 475 shares during the last quarter. Finally, Elevation Wealth Partners LLC increased its position in shares of DexCom by 61.0% in the 3rd quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock valued at $35,000 after purchasing an additional 152 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 2,565 shares of the stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $88.37, for a total value of $226,669.05. Following the transaction, the executive vice president directly owned 126,043 shares of the company’s stock, valued at $11,138,419.91. This trade represents a 1.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of DexCom stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total transaction of $549,537.56. Following the sale, the director owned 29,293 shares in the company, valued at $2,461,783.72. This represents a 18.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 22,822 shares of company stock worth $1,920,193. Corporate insiders own 0.28% of the company’s stock.

DexCom Stock Performance

Shares of DexCom stock opened at $82.97 on Wednesday. The firm has a market capitalization of $30.94 billion, a P/E ratio of 32.54, a P/E/G ratio of 1.40 and a beta of 1.45. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $92.59. The company has a quick ratio of 1.40, a current ratio of 1.74 and a debt-to-equity ratio of 0.49. The firm’s 50 day moving average is $85.51 and its two-hundred day moving average is $74.79.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, October 29th. The medical device company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.05. The company had revenue of $1.34 billion for the quarter, compared to analysts’ expectations of $1.33 billion. DexCom had a net margin of 19.42% and a return on equity of 37.77%. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter last year, the company earned $0.61 earnings per share. Research analysts forecast that DexCom, Inc. will post 2.68 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. TD Cowen restated a “buy” rating and issued a $95.00 price objective on shares of DexCom in a report on Friday, September 18th. Raymond James Financial reiterated a “strong-buy” rating and set a $97.00 target price (up from $94.00) on shares of DexCom in a research note on Friday. JPMorgan Chase & Co. increased their target price on DexCom from $82.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 30th. BTIG Research raised their price target on DexCom from $90.00 to $96.00 and gave the company a “buy” rating in a research note on Monday, October 12th. Finally, Benchmark lifted their price target on DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $95.50.

Key Stories Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom is set to launch its 15-day G7 continuous glucose monitoring system in Canada in November. The longer sensor wear period may improve convenience and broaden patient access, supporting international growth prospects. DexCom to Launch 15-Day G7 CGM System in Canada This November
• Positive Sentiment: Analyst sentiment remains favorable: Leerink Partners reaffirmed its Buy rating, while Canaccord Genuity raised its target to $97 and UBS lifted its target to $107, both maintaining Buy ratings. Higher targets signal continued analyst confidence in DexCom’s outlook. Leerink Partners Reaffirms Their Buy Rating on Dexcom Canaccord Genuity Group recommendations UBS Group recommendations
• Neutral Sentiment: DexCom launched a campaign inviting people in the global diabetes community to share their experiences. The initiative may support awareness and engagement, but no direct financial impact was specified. A Letter to Diabetes campaign

DexCom Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.